Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Front Plant Sci ; 13: 839270, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35392514

RESUMO

Temperature is the primary factor affecting the morpho-physiological, developmental, and yield attributes of soybean. Despite several temperature and soybean studies, functional relationships between temperature and soybean physiology and yield components are limited. An experiment was conducted to determine the optimum temperature for soybean gas exchange and yield components using indeterminate (Asgrow AG5332, AG) and determinate (Progeny P5333 RY, PR) growth habit cultivars. Plants grown outdoors were exposed to 5 day/night temperature treatments, 21/13, 25/17, 29/21, 33/25, and 37°C/29°C, from flowering to maturity using the sunlit plant growth chambers. Significant temperature and cultivar differences were recorded among all measured parameters. Gas exchange parameters declined with increasing temperature treatments during the mid-pod filling stage, and quadratic functions best described the response. The optimum temperature for soybean pod weight, number, and seed number was higher for AG than PR, indicating greater high-temperature tolerance. Soybean exposed to warmer parental temperature (37°C/29°C) during pod filling decreased significantly the transgenerational seed germination when incubated at 18, 28, and 38°C. Our findings suggest that the impact of temperature during soybean development is transferable. The warmer temperature has adverse transgenerational effects on seed germination ability. Thus, developing soybean genotypes tolerant to high temperatures will help growers to produce high-yielding and quality beans. The quantified temperature, soybean physiology, and yield components-dependent functional algorithms would be helpful to develop adaptation strategies to offset the impacts of extreme temperature events associated with future climate change.

2.
JAMA Oncol ; 8(3): 385-392, 2022 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-35050320

RESUMO

IMPORTANCE: Existing criteria to estimate the benefit of a therapy in patients with cancer rely almost exclusively on tumor size, an approach that was not designed to estimate survival benefit and is challenged by the unique properties of immunotherapy. More accurate prediction of survival by treatment could enhance treatment decisions. OBJECTIVE: To validate, using radiomics and machine learning, the performance of a signature of quantitative computed tomography (CT) imaging features for estimating overall survival (OS) in patients with advanced melanoma treated with immunotherapy. DESIGN, SETTING, AND PARTICIPANTS: This prognostic study used radiomics and machine learning to retrospectively analyze CT images obtained at baseline and first follow-up and their associated clinical metadata. Data were prospectively collected in the KEYNOTE-002 (Study of Pembrolizumab [MK-3475] Versus Chemotherapy in Participants With Advanced Melanoma; 2017 analysis) and KEYNOTE-006 (Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab [MK-3475] Compared to Ipilimumab in Participants With Advanced Melanoma; 2016 analysis) multicenter clinical trials. Participants included 575 patients with a diagnosis of advanced melanoma who were randomly assigned to training and validation sets. Data for the present study were collected from November 20, 2012, to June 3, 2019, and analyzed from July 1, 2019, to September 15, 2021. INTERVENTIONS: KEYNOTE-002 featured trial groups testing intravenous pembrolizumab, 2 mg/kg or 10 mg/kg every 2 or every 3 weeks based on randomization, or investigator-choice chemotherapy; KEYNOTE-006 featured trial groups testing intravenous ipilimumab, 3 mg/kg every 3 weeks and intravenous pembrolizumab, 10 mg/kg every 2 or 3 weeks based on randomization. MAIN OUTCOMES AND MEASURES: The performance of the signature CT imaging features for estimating OS at the month 6 posttreatment landmark in patients who received pembrolizumab was measured using an area under the time-dependent receiver operating characteristics curve (AUC). RESULTS: A random forest model combined 25 imaging features extracted from tumors segmented on CT images to identify the combination (signature) that best estimated OS with pembrolizumab in 575 patients. The signature combined 4 imaging features, 2 related to tumor size and 2 reflecting changes in tumor imaging phenotype. In the validation set (287 patients treated with pembrolizumab), the signature reached an AUC for estimation of OS status of 0.92 (95% CI, 0.89-0.95). The standard method, Response Evaluation Criteria in Solid Tumors 1.1, achieved an AUC of 0.80 (95% CI, 0.75-0.84) and classified tumor outcomes as partial or complete response (93 of 287 [32.4%]), stable disease (90 of 287 [31.3%]), or progressive disease (104 of 287 [36.2%]). CONCLUSIONS AND RELEVANCE: The findings of this prognostic study suggest that the radiomic signature discerned from conventional CT images at baseline and on first follow-up may be used in clinical settings to provide an accurate early readout of future OS probability in patients with melanoma treated with single-agent programmed cell death 1 blockade.


Assuntos
Melanoma , Humanos , Imunoterapia , Ipilimumab/efeitos adversos , Melanoma/diagnóstico por imagem , Melanoma/tratamento farmacológico , Critérios de Avaliação de Resposta em Tumores Sólidos , Estudos Retrospectivos
3.
Oman Med J ; 36(2): e238, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33768969

RESUMO

OBJECTIVES: Diabetes mellitus (DM) is one of the major chronic diseases with a world prevalence of 8.5%. Oman has shown a consistent rise in the prevalence of DM, reaching 14.5% in 2017. A major complication of DM is diabetic retinopathy (DR). There is limited information available about the prevalence of DR and its subtypes in Oman. This is the largest national study conducted to determine the prevalence of DR and its subtypes in Oman. METHODS: We extracted the records of 2000 Omani patients with DM and retrospectively screened for DR, non-proliferative diabetic retinopathy (NPDR), and proliferative diabetic retinopathy (PDR) reported between 2000 and 2017. The sample included patients from 79 medical centers from all governorates of Oman. A total of 616 patients were included in the study. We investigated the prevalence of DR among both genders and different age groups. We studied the association between the progression of DM into DR. RESULTS: The prevalence of DR, NPDR, and PDR within patients diagnosed with DM was 19.2% (95% confidence interval (CI): 16.2-22.5), 8.6% (95% CI: 6.6-11.1), and 1.3% (95% CI: 0.7-2.5), respectively. Moreover, females have shown a higher prevalence of any DR, compromising 60.2% of all patients diagnosed with DR, 62.3% of all NPDR patients, and 75.0% of all PDR patients. However, there was no significant association between sex and DR (p = 0.840). There was a significant association between having DM for 10 years and DR (p = 0.010). CONCLUSIONS: The prevalence of DR increased from 14.3% in 2003 to 19.3% in 2017. Effective health policies and screening programs should be employed to control the increased prevalence of DM and DR.

4.
Iran J Kidney Dis ; 13(4): 251-256, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-31422391

RESUMO

INTRODUCTION: to study the presentation, clinical course, laboratoryresults, imaging findings, medical and urological treatments ofidiopathic retroperitoneal fibrosis at our institution. METHODS: Between January 2006 and December 2017, medical recordsand operatives' notes of 116 patients with idiopathic retroperitonealfibrosis (IPRF) were reviewed retrospectively. Diagnosis was doneby clinical and radiological imaging that fulfilled a strict criterion.All patients were initiated on Prednisolone 60 mg for two months,and reduced until reaching 10 mg daily, with a total duration of24 months in the responding patients. Renal drainage was done incases of obstructed kidneys. To assess response, both laboratoryresults and imaging studies at initiation and after 4 months werereviewed and compared. RESULTS: Of 116 patients diagnosed with IRPF, eighty five (73.3%)were male and thirty one (26.7%) female, with mean ± SD age atpresentation was (50.5 ± 10.6) years. 79% of the patients complaintof abdominal and low back pain, 27% uremic symptoms, 10.3% hada new onset of hypertension, 3.4% presented with anejaculation,and 13.8% were totally asymptomatic. Uretric obstruction hadbeen resolved in 132 ureters after a mean of 152 days of treatment.Almost 30 % reduction in the fibrotic mass size was achieved in82 % of patients. CONCLUSION: Glucocorticoids is the the mainstay of treatment. Therenal function tests, of the vast majority of patients, normalizedwith treatment. Relapse may occur, so a follow-up over a longperiod of time is required. A high index of suspicion is neededfor diagnosis in asymptomatic patients.


Assuntos
Glucocorticoides/administração & dosagem , Prednisolona/administração & dosagem , Fibrose Retroperitoneal/diagnóstico , Fibrose Retroperitoneal/terapia , Obstrução Ureteral/tratamento farmacológico , Adulto , Idoso , Feminino , Humanos , Jordânia , Dor Lombar/etiologia , Masculino , Pessoa de Meia-Idade , Recidiva , Estudos Retrospectivos , Stents , Tomografia Computadorizada por Raios X , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...